{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:13Z","timestamp":1780649533100,"version":"3.54.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This systematic literature review investigated whether extended dosing intervals (EDIs) of pharmacological acromegaly treatments reduce patient burden and costs compared with standard dosing, while maintaining effectiveness.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>MEDLINE\/Embase\/the Cochrane Library (2001\u2013June 2021) and key congresses (2018\u20132021) were searched and identified systematic literature review bibliographies reviewed. Included publications reported on efficacy\/effectiveness, safety and tolerability, health-related quality of life (HRQoL), and patient-reported and economic outcomes in longitudinal\/cross-sectional studies in adults with acromegaly. Interventions included EDIs of pegvisomant, cabergoline, and somatostatin receptor ligands (SRLs): lanreotide autogel\/depot (LAN), octreotide long-acting release (OCT), pasireotide long-acting release (PAS), and oral octreotide; no comparator was required.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 35 publications reported on 27 studies: 3 pegvisomant monotherapy, 11 pegvisomant combination therapy with SRLs, 9 LAN, and 4 OCT; no studies reported on cabergoline, PAS, or oral octreotide at EDIs. Maintenance of normal insulin-like growth factor I (IGF-I) was observed in\u2009\u2265\u200970% of patients with LAN (1 study), OCT (1 study), and pegvisomant monotherapy (1 study). Achievement of normal IGF-I was observed in\u2009\u2265\u200970% of patients with LAN (3 studies) and pegvisomant in combination with SRLs (4 studies). Safety profiles were similar across EDI and standard regimens. Patients preferred and were satisfied with EDIs. HRQoL was maintained and cost savings were provided with EDIs versus standard regimens.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Clinical efficacy\/effectiveness, safety, and HRQoL outcomes in adults with acromegaly were similar and costs lower with EDIs versus standard regimens. Physicians may consider acromegaly treatment at EDIs, especially for patients with good disease control.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-022-01285-1","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T22:09:04Z","timestamp":1669759744000},"page":"9-41","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"M.","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5366-1353","authenticated-orcid":false,"given":"Z.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3570-1088","authenticated-orcid":false,"given":"K.","family":"Hanman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-6591","authenticated-orcid":false,"given":"K.","family":"Haria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-8986","authenticated-orcid":false,"given":"A.","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0407-953X","authenticated-orcid":false,"given":"S.","family":"Khawaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-5786","authenticated-orcid":false,"suffix":"Jr","given":"A.","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M.","family":"Gadelha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"issue":"11","key":"1285_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189\u20133202","journal-title":"J Clin Invest"},{"key":"1285_CR2","doi-asserted-by":"crossref","unstructured":"Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G et al (2022) Clinical biology of the pituitary adenoma. Endocr Rev bnac010","DOI":"10.1210\/endrev\/bnac010"},{"issue":"1","key":"1285_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13023-016-0516-x","volume":"11","author":"T Brue","year":"2016","unstructured":"Brue T, Castinetti F (2016) The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis 11(1):135","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1285_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12020-018-1764-4","volume":"63","author":"P Caron","year":"2019","unstructured":"Caron P, Brue T, Raverot G, Tabarin A, Cailleux A, Delemer B et al (2019) Signs and symptoms of acromegaly at diagnosis: the physician\u2019s and the patient\u2019s perspectives in the ACRO-POLIS study. Endocrine 63(1):120\u2013129","journal-title":"Endocrine"},{"issue":"4","key":"1285_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678","journal-title":"Rev Endocr Metab Disord"},{"issue":"4","key":"1285_CR6","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):e937\u2013e946","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1285_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DST, Fleseriu M (2019) Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev 40(1):268\u2013332","journal-title":"Endocr Rev"},{"issue":"2","key":"1285_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.14797\/mdcj-13-2-64","volume":"13","author":"MD Sharma","year":"2017","unstructured":"Sharma MD, Nguyen AV, Brown S, Robbins RJ (2017) Cardiovascular disease in acromegaly. Methodist Debakey Cardiovasc J 13(2):64\u201367","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"2","key":"1285_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107(2):297\u2013308","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1285_CR10","doi-asserted-by":"publisher","first-page":"E14","DOI":"10.3171\/2010.7.FOCUS10168","volume":"29","author":"S Manjila","year":"2010","unstructured":"Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR (2010) Pharmacological management of acromegaly: a current perspective. Neurosurg Focus 29(4):E14","journal-title":"Neurosurg Focus"},{"key":"1285_CR11","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Somatuline\u00ae Depot (lanreotide) Injection. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022074s011lbl.pdf. Accessed 7 Dec 2021"},{"key":"1285_CR12","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: Somatuline autogel 60mg, Somatuline autogel 90mg, Somatuline autogel 120mg. https:\/\/www.medicines.org.uk\/emc\/medicine\/25104#gref. Accessed 21 May 2021"},{"key":"1285_CR13","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Sandostatin LAR Depot (octreotide acetate) for injectable suspension, for gluteal intramuscular use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021008s043lbl.pdf. Accessed 7 Dec 2021"},{"key":"1285_CR14","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Signifor LAR (pasireotide) for Injectable Suspension, for Intramuscular Use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203255s000lbl.pdf. Accessed 7 Dec 2021"},{"key":"1285_CR15","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Mycapssa (octreotide) delayed-release capsules, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208232s000lbl.pdf. Accessed 24 June 2021"},{"issue":"2","key":"1285_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.17925\/EE.2013.09.02.132","volume":"9","author":"K Gariani","year":"2013","unstructured":"Gariani K, Meyer P, Philippe J (2013) Implications of somatostatin analogues in the treatment of acromegaly. Eur Endocrinol 9(2):132\u2013135","journal-title":"Eur Endocrinol"},{"issue":"1","key":"1285_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24(1):1\u201313","journal-title":"Pituitary"},{"key":"1285_CR18","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Somavert (pegvisomant) for injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021106s036lbl.pdf. Accessed 7 Dec 2021"},{"issue":"4","key":"1285_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Fuhrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185(4):525\u2013538","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1285_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","volume":"46","author":"M Marazuela","year":"2014","unstructured":"Marazuela M, Ramos-Lev\u00ed A, Sampedro-N\u00fa\u00f1ez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46(2):215\u2013219","journal-title":"Endocrine"},{"key":"1285_CR21","unstructured":"Health Sciences Authority. Somatuline autogel prolonged release solution for injection in a pre-filled syringe 120 mg (SIN14289P)."},{"issue":"5","key":"1285_CR22","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/00019053-199915050-00001","volume":"15","author":"DA Revicki","year":"1999","unstructured":"Revicki DA, Frank L (1999) Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. Pharmacoeconomics 15(5):423\u2013434","journal-title":"Pharmacoeconomics"},{"key":"1285_CR23","unstructured":"National Institute for Health Research (NIHR). Extended dosing intervals for treatments in acromegaly: a systematic review. PROSPERO 2021 CRD42021278922. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021278922. Accessed 23 Oct 2021"},{"key":"1285_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"1285_CR25","unstructured":"Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). https:\/\/training.cochrane.org\/handbook\/archive\/v6.2. Accessed 31 Aug 2022"},{"key":"1285_CR26","unstructured":"The Joanna Briggs Institute. Critical appraisal tools for use in JBI systematic reviews: Checklist for text and opinion. 2017. https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Text_and_Opinion2017_0.pdf. Accessed 21 May 2021"},{"key":"1285_CR27","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: Sandostatin LAR. https:\/\/www.medicines.org.uk\/emc\/medicine\/1321#gref. Accessed: 21 May 2021"},{"key":"1285_CR28","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: Signifor powder and solvent for injection. https:\/\/www.medicines.org.uk\/emc\/medicine\/30342. Accessed 21 May 2021"},{"key":"1285_CR29","unstructured":"United States Food and Drug Administration (US FDA). Highlights of Prescribing Information: Dostinex (cabergoline) tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020664s011lbl.pdf. Accessed 7 Dec 2021"},{"key":"1285_CR30","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: Dostinex Tablets. https:\/\/www.medicines.org.uk\/emc\/medicine\/10003. Accessed 21 May 2021"},{"key":"1285_CR31","unstructured":"European Medicines Agency (EMA). Summary of product characteristics: SOMAVERT 10mg powder and solvent for solution for injection. https:\/\/www.medicines.org.uk\/emc\/product\/64\/smpc. Accessed 21 May 2021"},{"key":"1285_CR32","volume-title":"Systematic reviews: CRD's guidance for undertaking reviews in health care","author":"Centre for Reviews and Dissemination","year":"2008","unstructured":"Centre for Reviews and Dissemination (2008) Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination, University of York, York"},{"key":"1285_CR33","unstructured":"Kmet LM, Lee RC, Cook LS (2004) Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR\u2014HTA Initiative #13"},{"key":"1285_CR34","unstructured":"XE.com Inc. Historic rate tables. https:\/\/www.xe.com\/currencytables\/?from=USD&date=2003-01-01#table-section. Accessed 13 June 2022"},{"key":"1285_CR35","first-page":"P1101","volume":"63","author":"F Dassie","year":"2019","unstructured":"Dassie F, Rosson M, Parolin M, Russo L, Mazzocut S, Martini C et al (2019) Pegvisomant: daily versus non daily administration a single centre real life study. Endocr Abstr 63:P1101","journal-title":"Endocr Abstr"},{"issue":"1","key":"1285_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EJE-08-0990","volume":"161","author":"CE Higham","year":"2009","unstructured":"Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ (2009) Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 161(1):21\u201325","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1285_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/EJE-15-1150","volume":"174","author":"A Muhammad","year":"2016","unstructured":"Muhammad A, Van Der Lely AJ, O\u2019Connor RD, Delhanty PJ, Dal J, Dallenga AH et al (2016) What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy? Eur J Endocrinol 174(5):663\u2013667","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"1285_CR38","doi-asserted-by":"publisher","first-page":"E3236","DOI":"10.1210\/clinem\/dgaa444","volume":"105","author":"V Bonert","year":"2020","unstructured":"Bonert V, Mirocha J, Carmichael J, Yuen KCJ, Araki T, Melmed S (2020) Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. J Clin Endocrinol Metab 105(9):E3236\u2013E3245","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1285_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s11102-019-00943-1","volume":"22","author":"R Camara","year":"2019","unstructured":"Camara R, Venegas E, Garcia-Arnes JA, Cordido F, Aller J, Samaniego ML et al (2019) Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. Pituitary 22(2):137\u2013145","journal-title":"Pituitary"},{"issue":"4","key":"1285_CR40","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5603\/EP.a2019.0023","volume":"70","author":"A Colao","year":"2019","unstructured":"Colao A, Zgliczy\u0144ski W, Komorowski J, Kos-Kud\u0142a B, Tabarin A, Kerlan V et al (2019) Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. Endokrynol Pol 70(4):305\u2013312","journal-title":"Endokrynol Pol"},{"issue":"5","key":"1285_CR41","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1530\/EJE-15-0519","volume":"173","author":"SE Franck","year":"2015","unstructured":"Franck SE, van der Lely AJ, Delhanty PJ, Jorgensen JO, Neggers SJ (2015) Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3. Eur J Endocrinol 173(5):553\u2013561","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1285_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12020-020-02501-3","volume":"71","author":"E Kuhn","year":"2021","unstructured":"Kuhn E, Caron P, Delemer B, Raingeard I, Lefebvre H, Raverot G et al (2021) Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine 71(1):158\u2013167","journal-title":"Endocrine"},{"issue":"8","key":"1285_CR43","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1210\/jc.2011-0654","volume":"96","author":"M Madsen","year":"2011","unstructured":"Madsen M, Poulsen PL, Orskov H, M\u00f8ller N, J\u00f8rgensen JO (2011) Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients. J Clin Endocrinol Metab 96(8):2405\u20132413","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1285_CR44","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen J et al (2018) Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study). J Clin Endocrinol Metab 103(2):586\u2013595","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1285_CR45","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1530\/EJE-08-0843","volume":"160","author":"SJ Neggers","year":"2009","unstructured":"Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160(4):529\u2013533","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"1285_CR46","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1210\/jc.2008-0669","volume":"93","author":"SJ Neggers","year":"2008","unstructured":"Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X et al (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853\u20133859","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1285_CR47","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1210\/jc.2007-1234","volume":"92","author":"SJ Neggers","year":"2007","unstructured":"Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598\u201345601","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1285_CR48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-10-0867","volume":"164","author":"AJ Van Der Lely","year":"2011","unstructured":"Van Der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J et al (2011) Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325\u2013333","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1285_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1530\/EJE-07-0366","volume":"157","author":"P Abrams","year":"2007","unstructured":"Abrams P, Alexopoulou O, Abs R, Maiter D, Verhelst J (2007) Optimalization and cost management of lanreotide-autogel therapy in acromegaly. Eur J Endocrinol 157(5):571\u2013577","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1285_CR50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.endinu.2018.12.004","volume":"66","author":"C Alvarez-Escola","year":"2019","unstructured":"Alvarez-Escola C, Venegas-Moreno EM, Garcia-Arnes JA, Blanco-Carrera C, Marazuela-Azpiroz M, Galvez-Moreno MA et al (2019) ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide autogel treatment in Spanish patients with acromegaly. Endocrinol Diabetes Nutr 66(5):320\u2013329","journal-title":"Endocrinol Diabetes Nutr"},{"issue":"3","key":"1285_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s12020-020-02424-z","volume":"70","author":"I Bernab\u00e9u","year":"2020","unstructured":"Bernab\u00e9u I, Fajardo C, Marazuela M, Cordido F, Venegas EM, de Pablos-Velasco P et al (2020) Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. Endocrine 70(3):575\u2013583","journal-title":"Endocrine"},{"issue":"2","key":"1285_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","volume":"71","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F et al (2009) Significant tumour shrinkage after 12 months of lanreotide autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol 71(2):237\u2013245","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1285_CR53","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/BF03346453","volume":"32","author":"G Lombardi","year":"2009","unstructured":"Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M et al (2009) Efficacy of the new long-acting formulation of lanreotide (Lanreotide autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 32(3):202\u2013209","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1285_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1365-2265.2006.02595.x","volume":"65","author":"T Lucas","year":"2006","unstructured":"Lucas T, Astorga R, Almeida R et al (2006) Efficacy of lanreotide autogel administered every 4\u20138 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: A phase III trial. Clin Endocrinol 65(3):320\u2013326","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1285_CR55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1530\/EJE-15-0215","volume":"173","author":"SJ Neggers","year":"2015","unstructured":"Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, Bronstein MD et al (2015) Lanreotide autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol 173(3):313\u2013323","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1285_CR56","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1365-2265.2007.02917.x","volume":"67","author":"CL Ronchi","year":"2007","unstructured":"Ronchi CL, Boschetti M, Uberti ECD, Mariotti S, Grottoli S, Loli P et al (2007) Efficacy of a slow-release formulation of lanreotide (autogel 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol 67(4):512\u2013519","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1285_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/s-0030-1267244","volume":"119","author":"J Schopohl","year":"2011","unstructured":"Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M et al (2011) Efficacy and acceptability of lanreotide autogel 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 119(3):156\u2013162","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"1285_CR58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1365-2265.2003.01710.x","volume":"58","author":"NR Biermasz","year":"2003","unstructured":"Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA et al (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol 58(3):288\u2013295","journal-title":"Clin Endocrinol"},{"issue":"3","key":"1285_CR59","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s11102-014-0570-0","volume":"18","author":"AL Espinosa-de-los-Monteros","year":"2015","unstructured":"Espinosa-de-los-Monteros AL, Gonzalez B, Vargas G, Sosa E, Mercado M (2015) Octreotide LAR treatment of acromegaly in \u201creal life\u201d: long-term outcome at a tertiary care center. Pituitary 18(3):290\u2013296","journal-title":"Pituitary"},{"issue":"3","key":"1285_CR60","first-page":"291","volume":"45","author":"IA Martinez-Delgado","year":"2007","unstructured":"Martinez-Delgado IA, Gomez-Martinez G (2007) Usefulness of GH and IGF-1 to establish the dose and frequency of application of octreotide to treat acromegaly. Rev Med Inst Mex Seguro Soc 45(3):291\u2013295 (in Spanish)","journal-title":"Rev Med Inst Mex Seguro Soc."},{"issue":"2","key":"1285_CR61","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2265.2004.02084.x","volume":"61","author":"HE Turner","year":"2004","unstructured":"Turner HE, Thornton-Jones VA, Wass JA (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol 61(2):224\u2013231","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1285_CR62","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4187\/respcare.03272","volume":"60","author":"A Zanini","year":"2015","unstructured":"Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Della Patrona S et al (2015) Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care 60(1):88\u201395","journal-title":"Respir Care"},{"issue":"9","key":"1285_CR63","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"1285_CR64","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D et al (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509\u20131517","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1285_CR65","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A et al (2014) Acromegaly: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1285_CR66","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","volume":"14","author":"LFS Grasso","year":"2015","unstructured":"Grasso LFS, Auriemma RS, Pivonello R, Colao A (2015) Adverse events associated with somatostatin analogs in acromegaly. Expert Opin Drug Saf 14(8):1213\u20131226","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1285_CR67","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s11102-020-01102-7","volume":"24","author":"N Prencipe","year":"2021","unstructured":"Prencipe N, Bona C, Cuboni D, Parasiliti-Caprino M, Berton AM, Fenoglio LM et al (2021) Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. Pituitary 24(2):242\u2013251","journal-title":"Pituitary"},{"issue":"3","key":"1285_CR68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","volume":"14","author":"A Ben-Shlomo","year":"2011","unstructured":"Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284\u2013294","journal-title":"Pituitary"},{"issue":"2","key":"1285_CR69","first-page":"117","volume":"92","author":"LA Anghel","year":"2019","unstructured":"Anghel LA, Farcas AM, Oprean RN (2019) An overview of the common methods used to measure treatment adherence. Med Pharm Rep 92(2):117\u2013122","journal-title":"Med Pharm Rep"},{"key":"1285_CR70","first-page":"429","volume":"44","author":"M Ortiz","year":"2015","unstructured":"Ortiz M (2015) Benefits of less frequent injections in advanced prostate cancer. Aust J Gen Pract 44:429\u2013430","journal-title":"Aust J Gen Pract"},{"key":"1285_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/IJGM.S38594","volume":"6","author":"DT Adelman","year":"2013","unstructured":"Adelman DT, Liebert KJ, Nachtigall LB, Lamerson M, Bakker B (2013) Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment. Int J Gen Med 6:31\u201338","journal-title":"Int J Gen Med"},{"issue":"2","key":"1285_CR72","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11102-021-01198-5","volume":"25","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Barkan A, Del Pilar SM, Darhi Y, de Pierrefeu A, Ribeiro-Oliveira A Jr et al (2022) Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary 25(2):296\u2013307","journal-title":"Pituitary"},{"issue":"2","key":"1285_CR73","doi-asserted-by":"publisher","first-page":"ofc035","DOI":"10.1093\/ofid\/ofv035","volume":"2","author":"B Duerden","year":"2015","unstructured":"Duerden B, Fry C, Johnson AP, Wilcox MH (2015) The control of methicillin-resistant staphylococcus aureus blood stream infections in England. Open Forum Infect Dis. 2(2):ofc035","journal-title":"Open Forum Infect Dis."},{"issue":"4","key":"1285_CR74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11102-020-01059-7","volume":"23","author":"M Fleseriu","year":"2020","unstructured":"Fleseriu M, Buchfelder M, Cetas JS, Fazeli PK, Mallea-Gil SM, Gurnell M et al (2020) Pituitary Society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary 23(4):327\u2013337","journal-title":"Pituitary"},{"issue":"2","key":"1285_CR75","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12020-020-02565-1","volume":"71","author":"A Giustina","year":"2021","unstructured":"Giustina A, Legg E, Cesana BM, Frara S, Mortini P, Fleseriu M (2021) Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. Endocrine 71(2):273\u2013280","journal-title":"Endocrine"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01285-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01285-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T16:08:32Z","timestamp":1676131712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01285-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1285"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01285-1","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"14 October 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MF: Scientific Consultant for Amryt (Chiasma), Crinetics, Ionis, Ipsen, Pfizer, and Recordati; Principal Investigator with support to the institution for Chiasma, Crinetics, Ionis, and Recordati; on the Editorial Board of\u00a0<i>Pituitary<\/i>; KaH, KeH: Employees of Costello Medical; AH: Employee of Ipsen; Holds Ipsen stocks; SK: Chair of World Alliance of Pituitary Organizations; ARO: Employee of Ipsen; Holds Ipsen stocks; ZZ: Speaker fee; Self; Novartis, Ipsen; MG: Speaker fee; Self; Novartis, Recordati, Ipsen, Crinetics, Novo Nordisk. Advisory board attendee; Self; Novartis, Novo Nordisk, Recordati and Crinetics Pharmaceuticals; Principal Investigator; Self; Recordati, Crinetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}